CN119923392A - 表皮生长因子受体抑制剂的盐和晶体形式 - Google Patents

表皮生长因子受体抑制剂的盐和晶体形式 Download PDF

Info

Publication number
CN119923392A
CN119923392A CN202380051632.8A CN202380051632A CN119923392A CN 119923392 A CN119923392 A CN 119923392A CN 202380051632 A CN202380051632 A CN 202380051632A CN 119923392 A CN119923392 A CN 119923392A
Authority
CN
China
Prior art keywords
egfr
mesylate salt
crystalline
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380051632.8A
Other languages
English (en)
Chinese (zh)
Inventor
E·格鲁夫
匡善明
A·潘迪
H·沙赫
谢天
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cable Chart Pharmaceutical Co
Original Assignee
Cable Chart Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cable Chart Pharmaceutical Co filed Critical Cable Chart Pharmaceutical Co
Publication of CN119923392A publication Critical patent/CN119923392A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202380051632.8A 2022-05-04 2023-05-04 表皮生长因子受体抑制剂的盐和晶体形式 Pending CN119923392A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338371P 2022-05-04 2022-05-04
US63/338,371 2022-05-04
PCT/US2023/020925 WO2023215431A1 (en) 2022-05-04 2023-05-04 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
CN119923392A true CN119923392A (zh) 2025-05-02

Family

ID=86688767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380051632.8A Pending CN119923392A (zh) 2022-05-04 2023-05-04 表皮生长因子受体抑制剂的盐和晶体形式

Country Status (12)

Country Link
US (1) US20250282761A1 (enExample)
EP (1) EP4519254A1 (enExample)
JP (1) JP2025517634A (enExample)
KR (1) KR20250012078A (enExample)
CN (1) CN119923392A (enExample)
AU (1) AU2023265064A1 (enExample)
CA (1) CA3251624A1 (enExample)
IL (1) IL316663A (enExample)
MX (1) MX2024013485A (enExample)
TW (1) TW202409016A (enExample)
UY (1) UY40256A (enExample)
WO (1) WO2023215431A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097270A1 (en) * 2022-11-01 2024-05-10 Blueprint Medicines Corporation Egfr inhibitors for treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493419A (zh) * 2020-03-18 2021-10-12 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
IL302457A (en) * 2020-10-30 2023-06-01 Blueprint Medicines Corp Pyrimidine compounds, preparations and their medical applications
CA3196857A1 (en) * 2020-10-30 2022-05-05 Gurulingappa Hallur Pyrimidine compounds, compositions, and medicinal applications thereof

Also Published As

Publication number Publication date
TW202409016A (zh) 2024-03-01
AU2023265064A1 (en) 2024-11-14
US20250282761A1 (en) 2025-09-11
MX2024013485A (es) 2024-12-06
IL316663A (en) 2024-12-01
WO2023215431A1 (en) 2023-11-09
EP4519254A1 (en) 2025-03-12
JP2025517634A (ja) 2025-06-10
KR20250012078A (ko) 2025-01-23
CA3251624A1 (en) 2023-11-09
UY40256A (es) 2023-11-15

Similar Documents

Publication Publication Date Title
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
US9630952B2 (en) Crystalline forms of afatinib di-maleate
WO2021073498A1 (zh) Egfr抑制剂、组合物及其制备方法
JP2019518776A (ja) Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶
TWI774758B (zh) C5-苯胺喹唑啉化合物及其治療癌症之用途
WO2021213317A1 (zh) Hpk1抑制剂及其制备方法和用途
TWI732431B (zh) 多形體
US12227491B2 (en) EGFR inhibitors
JP2019507776A (ja) ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用
CN102070618B (zh) 一种化合物及其晶体
EP4359400B1 (en) Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
JP7430656B2 (ja) Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
CN109593102A (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
TWI914461B (zh) 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
TW202402757A (zh) ７Ｈ－吡咯［２，３－ｄ〕嘧啶－４－胺衍生物之結晶
WO2011158931A1 (ja) インダゾール誘導体の有用な塩
JP2023505254A (ja) ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドを製造するための方法
WO2026082074A1 (zh) Parg抑制剂的盐型、晶型及其组合物、制备方法和应用
WO2025231053A1 (en) Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
JP2026502614A (ja) Ｃｄｋ阻害剤およびその薬学的に許容される塩の結晶形ならびにそれらの使用
HK40104230A (zh) 表皮生长因子受体抑制剂的盐和晶体形式
HK1260821B (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination